A Registry Study on Genetics and Biomarkers of Acute Coronary Syndrome
NCT ID: NCT03752515
Last Updated: 2023-10-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2000 participants
OBSERVATIONAL
2015-06-02
2025-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Coronary Syndrome Genetic Study
NCT01964313
Prospective Registry of the Current Status of Care for Patients With Coronary Artery Disease
NCT05337319
Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome
NCT04184583
A Cohort of Patients Undergoing Percutaneous Coronary Intervention
NCT05719545
China Acute Myocardial Infarction Registry
NCT01874691
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
case-ACS-MACE
ACS patients with poor prognosis
No interventions assigned to this group
control-ACS-MACE
ACS patients with good prognosis
No interventions assigned to this group
Health-control
general population without ACS
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Contact Order Form has been provided.
* Aged 18 years or older.
* Hospitalized within 48 hours of onset of symptoms.
* Diagnosis of STEMI, NSTEMI or UA using the following definitions:
1.Criteria for STEMI diagnosis:
1. History of chest pain/discomfort and
2. Persistent ST-segment elevation (\> 30 min) of ≥ 0.1 mV in 2 or more contiguous ECG leads or presumed new left bundle branch block (LBBB) on admission and
3. Elevation of cardiac biomarkers (CK-MB, troponins): at least one value above the 99th percentile of the local laboratory upper reference limit.
2.Criteria for NSTEMI diagnosis:
1.History of chest pain/discomfort and 2.Lack of persistent ST-segment elevation, LBBB or intraventricular conduction disturbances and 3.Elevation of cardiac biomarkers (CK-MB, troponins): at least one value above the 99th percentile of the local laboratory upper reference limit. 3.Criteria for Unstable Angina diagnosis:
1. Symptoms of angina at rest or on minimal exercise and
2. At least 0.5mm ST deviation in at least 2 leads and
3. No increase in biomarkers of necrosis
4. OR objective evidence of ischaemia by non-invasive imaging OR significant coronary stenosis as determined by the treating physician at angiography if this is standard practice in study site.
* Age and gender are matched with cases.
* No Coronary Artery Disease was detected by Coronary CT examination.
* Normal biochemical indicators.
Exclusion Criteria
* UA, STEMI and NSTEMI occurring in patients already hospitalized for other reasons.
* Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances).
* Presence of serious/severe co-morbidities in the opinion of the investigator which may limit short term (i.e. 6 month) life expectancy.
* Current participation in a randomised interventional clinical trial.
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Institute of Heart, Lung and Blood Vessel Diseases
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jie Du, PHD
Role: STUDY_DIRECTOR
Beijing Anzhen Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Anzhen Hospital
Beijing, , China
Beijing Luhe Hospital, Capital Medical University
Beijing, , China
The First Affiliated Hospital of Dalian Medical University
Dalian, , China
The Second Hospital of Dalian Medical University
Dalian, , China
The First Hospital of Jilin University
Jilin, , China
People's Hospital of Henan University
Zhengzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ma J, Ma K, Chen J, Yang X, Gao F, Gao H, Zhang H, Ma XL, Du J, Li P, Li Y. Development and Validation of Risk Stratification for Heart Failure After Acute Coronary Syndrome Based on Dynamic S100A8/A9 Levels. J Am Heart Assoc. 2025 Feb 4;14(3):e037401. doi: 10.1161/JAHA.124.037401. Epub 2025 Feb 3.
Li Y, Chen B, Yang X, Zhang C, Jiao Y, Li P, Liu Y, Li Z, Qiao B, Bond Lau W, Ma XL, Du J. S100a8/a9 Signaling Causes Mitochondrial Dysfunction and Cardiomyocyte Death in Response to Ischemic/Reperfusion Injury. Circulation. 2019 Aug 27;140(9):751-764. doi: 10.1161/CIRCULATIONAHA.118.039262. Epub 2019 Jun 21.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BeijingIHLBVD2018010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.